For Patients &

Our sight is the most perfect and most delightful of all our senses.

Joseph Addison

See Hope

Our ability to see clearly affects nearly every aspect of our daily lives. Without our vision, the ability to do even the simplest of tasks becomes a challenge, drastically shifting our quality of life. Losing vision remains one of the biggest medical fears for people spanning the globe. This is why ocular diseases – especially those that lead to progressive vision loss and blindness – have such a profound, societal impact. Around the world and across healthcare systems, the need for optimal treatments for a range of ocular diseases remains immense. This is especially true of conditions that require ongoing, invasive, repeat treatments in a clinical setting to preserve and protect sight.

Now picture this: A future where wet AMD patients no longer need to get injected every 4 to 12 weeks for as long as they live. Millions of people living without the fear of losing their independence and being unable to see their spouses, children, grandkids, and friends.

Adverum envisions a world where our new gene therapy may replace the current standard of care for wet AMD – frequent injections of anti-vascular endothelial growth factor (anti-VEGF) agents – with a single treatment that could maintain vision for years versus weeks.

We can’t imagine a more beautiful sight than making our vision a reality.


Things to Know about Wet AMD

  • Wet AMD is a progressive disease that affects the macula, the region of the retina at the back of the eye responsible for central vision.
  • Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with this condition.i
  • The incidence of new cases of wet AMD is expected to grow significantly worldwide as populations age.i,ii
  • AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases.ii


Reasons a New Therapy is Needed for Vision-Threatening Eye Diseases like Wet AMD

  • Although the current standard of care – ocular injections of anti-VEGF agents to inhibit the growth of blood vessels and prevent fluid leakage – is effective in the short-term, it requires visits to the doctor every 4 to 12 weeks for more injections.
  • Complying with this regimen can be difficult for patients and their caregivers – patients have reported that average therapy visits can require as much as 12 hours of their time.iii
  • As a result, many patients skip or discontinue scheduled treatments, which leads to underdosing that can cause loss of vision.
  • Retina specialists report that decreasing the frequency of injections is by far the largest unmet need for wet AMD patients.iv
  • Studies of anti-VEGF treatments suggest that gains in visual acuity were largely lost in two-thirds of patients who were followed for more than 7 years.v

Our Commitment

Adverum is committed to developing lifelong, regenerative therapies that may preserve patient sight and help wet AMD patients improve their quality of life. To learn more about our active clinical trials, visit our Pipeline page or contact us.

i Bright Focus Foundation. Age-Related Macular Degeneration: Facts & Figures. [Internet; cited October 2021]. Available from
ii Wong WL, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:106–16.
iii American Macular Degeneration Foundation (AMDF) Website. Accessed on 18 December 2020 at
iv Scott AW, Bressler MN, Ffolkes S, Wittenborn JS, Jorkasky J. Public attitudes about eye and vision health. JAMA Ophthalmology. 2016;132(10):1111-1118.
v ADVM third-party market research.